The price of Rigel Pharmaceuticals (NASDAQ: RIGL) closed at $1.15 in the last session, down -4.17% from day before closing price of $1.20. On the day, 767514 shares were traded. RIGL stock price reached its highest trading level at $1.1900 during the session, while it also had its lowest trading level at $1.1400.
Ratios:
We take a closer look at RIGL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.76 and its Current Ratio is at 1.86.
Piper Sandler Downgraded its Overweight to Neutral on June 08, 2022, whereas the target price for the stock was revised from $7 to $1.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 05 ’24 when RODRIGUEZ RAUL R sold 30,545 shares for $1.14 per share. The transaction valued at 34,821 led to the insider holds 2,036,629 shares of the business.
Santos David A sold 8,918 shares of RIGL for $10,167 on Feb 05 ’24. The EVP, Chief Commercial Officer now owns 349,093 shares after completing the transaction at $1.14 per share. On Feb 05 ’24, another insider, Schorno Dean L, who serves as the EVP & Chief Financial Officer of the company, sold 7,027 shares for $1.14 each. As a result, the insider received 8,011 and left with 402,891 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.73.
Stock Price History:
Over the past 52 weeks, RIGL has reached a high of $1.96, while it has fallen to a 52-week low of $0.71.
Shares Statistics:
A total of 174.83M shares are outstanding, with a floating share count of 171.94M. Insiders hold about 1.96% of the company’s shares, while institutions hold 60.97% stake in the company.
Earnings Estimates
The company has Transocean Ltd (Switzerland) analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $1.15, with high estimates of $3.16 and low estimates of $0.11.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
